Trevi Therapeutics (TRVI) Analysts See $29 Target, Implying a +102% Upside

Key Takeaways

• The central stock price target of $29 is the arithmetic mean of 11 verified analyst price targets, which range from a low of $23 to a high of $40.
• With the latest verified price near $14.33, reaching $29 would require a gain of roughly 102% — a very large move that would more than double the shares.
• The 11 reviewed targets carry only Buy-equivalent ratings, reflecting broad confidence in Haduvio, an investigational chronic cough therapy with no FDA-approved competitor in its lead indications.
• Supporting factors include a clean competitive landscape after two rival programs failed, a cash runway into 2030, and multiple Phase 3 readouts expected in 2027 and 2028.
• The biggest risks are binary clinical trial outcomes, pre-revenue status, ongoing cash burn, and the historical difficulty of chronic cough drug development.
• The wide $23-to-$40 range shows genuine disagreement about how aggressively to value a company whose key data still lies years ahead.
• For more detail, explore Trevi's Major News, Today's Price Move, Forecast, and Earnings pages.
• For additional perspective on market timing and opportunity scanning, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine extended-release) for chronic cough tied to idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough (RCC). Because it generates no product revenue, its valuation rests almost entirely on clinical and regulatory expectations rather than earnings.

Across the most recent coverage, 11 analyst targets remain in place, ranging from $23 to $40. The arithmetic mean is $29, which becomes the central target used here. Views are uniformly bullish — every covering analyst holds a Buy or equivalent rating — yet the spread is wide. Morgan Stanley (Judah Frommer) and Needham sit at the conservative end near $23, while BMO Capital initiated coverage with a $36 target and Raymond James (Ryan Deschner) carries the high at $40. In between, H.C. Wainwright, Oppenheimer, JonesTrading, Clear Street, Cantor Fitzgerald, Stifel, and B. Riley hold targets from $24 to $31. Recent actions were predominantly upward, including BMO's $36 initiation and Raymond James's raise to $40, reflecting a competitive landscape that cleared after rival chronic cough programs failed. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The stock last traded near $14.33, roughly midway in a 52-week range of $8.46 to $20.22. Reaching the $29 central target would require an advance of approximately 102%, a very large move by any standard and one that would carry the shares well beyond their prior 52-week high. The path depends on clinical execution: OCEAN-2 Phase 3 top-line data in IPF-related chronic cough are expected in the second half of 2027, OCEAN-1 in the first half of 2028, and full Phase 2b LAKE results in RCC in the second half of 2027. Any positive readout could trigger a re-rating, but the stock carries no near-term earnings to anchor valuation.

What Could Support a Move Toward the Target

The bull case is unusually concentrated. Haduvio has shown statistically significant cough-frequency reductions in both IPF and RCC patients, and after two competing programs failed, Trevi is effectively alone across its targeted chronic cough indications. Management cites a cash position of roughly $299 million at the end of the third quarter, providing runway into 2030 and through potential FDA approval of the IPF program. A recent FDA alignment on a Phase 2 dose-ranging study in non-IPF ILD also broadens the addressable market, which management estimates is more than double the IPF opportunity. Analysts such as BMO emphasize Haduvio's first-in-class potential in a high-unmet-need market with no approved therapy. From what I see, the cleared competitive field stands out as a meaningful differentiator here.

What Could Prevent the Target From Being Reached

The risks are equally concentrated. Trevi Therapeutics (TRVI) is pre-revenue and will post losses for years, with research and development spending rising as trials expand. Chronic cough development has a poor record — very few trials have succeeded, and placebo response and patient heterogeneity remain persistent obstacles. The upcoming sample-size re-estimation (SSRE) for the LAKE trial could, in a worst case, signal futility. Regulatory approval is not guaranteed, and any trial failure, enrollment delay, or safety issue could sharply compress the stock toward its lower analyst targets. The $23 floor on the target range reflects precisely this uncertainty.

Technical Levels and Market Structure

From a technical standpoint, the shares sit below the $20.22 52-week high, which now functions as a notable resistance zone; the $29 target sits well above that prior peak. Recent consolidation near the $13-to-$14 area offers a nearer-term reference, with the $8.46 52-week low representing the downside extreme. Because biotech price action is driven primarily by data events rather than chart structure, these levels matter less than upcoming trial readouts.

Time Horizon and What Investors Should Monitor

Analyst targets generally reflect a roughly 12-month research horizon, though for a company whose pivotal data land in late 2027 and 2028, the targets implicitly look across multiple catalysts rather than a single quarter. Investors should monitor the LAKE SSRE outcome expected in early 2027, enrollment updates on OCEAN-1 and OCEAN-2, the Q1 2027 start of the non-IPF ILD Phase 2 study, quarterly cash-burn disclosures, and any analyst target revisions that follow clinical or regulatory news. I’m watching the upcoming data milestones closely for any shifts in sentiment.

Final Assessment

The question of whether Trevi Therapeutics can reach $29 ultimately depends on clinical outcomes that no model can predict in advance. The central target — the $29 mean of 11 analyst price targets spanning $23 to $40 — implies a doubling from current levels and is anchored to Haduvio's first-in-class potential, a cleared competitive field, and funding through key milestones. Yet the wide range and uniformly binary nature of biotech catalysts underscore that this is a high-risk, high-reward setup. A positive OCEAN or LAKE readout would meaningfully narrow the distance to the target, while a failure could erase much of it. Investors should weigh both possibilities against their own risk tolerance and monitor the catalysts above.

Using Tickeron AI Daily Buy/Sell Signals for Additional Perspective

I often rely on Tickeron’s AI Daily Buy/Sell Signals to get a more systematic view of TRVI and thousands of other stocks. These tools apply artificial intelligence to track evolving market conditions, technical behavior, and data-driven analysis, producing Buy, Sell, or Hold signals as conditions change. This approach helps me spot potential opportunities and shifts in trends alongside my fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume